Evidence map›Paper›PMID 33251142›Full record

ArticleFrontiers in oncology2020

T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis.

Bing Kang, Cong Sun, Hui Gu, Shifeng Yang, Xianshun Yuan, Congshan Ji, Zhaoqin Huang, Xinxin Yu, Shaofeng Duan, Ximing Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bing KangSchool of Medicine, Shandong University, Jinan, China.
Cong SunDepartment of Radiology, Shandong Medical Imaging Research Institute, Jinan, China.
Hui GuDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Shifeng YangDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Xianshun YuanDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Congshan JiDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Zhaoqin HuangDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Xinxin YuSchool of Medicine, Shandong University, Jinan, China.
Shaofeng DuanGE Healthcare, Shanghai, China.
Ximing WangSchool of Medicine, Shandong University, Jinan, China.
Shandong University · CNShandong Provincial Hospital · CNUnited Imaging Healthcare (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop and validate a radiomics nomogram to improve prediction of recurrence and metastasis risk in T1 stage clear cell renal cell carcinoma (ccRCC).

methodsThis retrospective study recruited 168 consecutive patients (mean age, 53.9 years; range, 28-76 years; 43 women) with T1 ccRCC between January 2012 and June 2019, including 50 aggressive ccRCC based on synchronous metastasis or recurrence after surgery. The patients were divided into two cohorts (training and validation) at a 7:3 ratio. Radiomics features were extracted from contrast enhanced CT images. A radiomics signature was developed based on reproducible features by means of the least absolute shrinkage and selection operator method. Demographics, laboratory variables (including sex, age, Fuhrman grade, hemoglobin, platelet, neutrophils, albumin, and calcium) and CT findings were combined to develop clinical factors model. Integrating radiomics signature and independent clinical factors, a radiomics nomogram was developed. Nomogram performance was determined by calibration, discrimination, and clinical usefulness.

resultsTen features were used to build radiomics signature, which yielded an area under the curve (AUC) of 0.86 in the training cohort and 0.85 in the validation cohort. By incorporating the sex, maximum diameter, neutrophil count, albumin count, and radiomics score, a radiomics nomogram was developed. Radiomics nomogram (AUC: training, 0.91; validation, 0.92) had higher performance than clinical factors model (AUC: training, 0.86; validation, 0.90) or radiomics signature as a means of identifying patients at high risk for recurrence and metastasis. The radiomics nomogram had higher sensitivity than clinical factors mode (McNemar's chi-squared = 4.1667, p = 0.04) and a little lower specificity than clinical factors model (McNemar's chi-squared = 3.2, p = 0.07). The nomogram showed good calibration. Decision curve analysis demonstrated the superiority of the nomogram compared with the clinical factors model in terms of clinical usefulness.

conclusionThe CT-based radiomics nomogram could help in predicting recurrence and metastasis risk in T1 ccRCC, which might provide assistance for clinicians in tailoring precise therapy.

Indexed as

clear cell renal cell carcinomacomputed tomographyneoplasm metastasisprediction modelrecurrence

Identifiers

PMID33251142
PMCPMC7672185
OpenAlexW3097394391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.